



Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

November 7, 2024

BOULDER, Colo., Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 9:30 a.m. GMT. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at <https://ir.enliventherapeutics.com/>. The webcast will be archived for a period of 90 days following the conclusion of the live event.

About Enliven

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/enliven-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-302299207.html>

SOURCE Enliven Therapeutics, Inc.

Contact:

Investors

ir@enliventherapeutics.com

Media

media@enliventherapeutics.com

